|
|
|
| Clinical effect of Gonadotropin-releasing Hormone Analogues combined with Growth Hormone in the treatment of idiopathic central precocious puberty |
| ZHONG Xiu-ling1 LI Liu-shao2 LI Yu-feng1 CHENG Shuang-xi1 |
| 1. Department of Child Healthcare, Maternal and Child Health Care Hospital of Dongguan City in Guangdong Province,Dongguan 523000, China; 2. Department of Child Healthcare, Dalingshan Hospital of Dongguan City in Guangdong Province, Dongguan 523820, China |
|
|
|
|
Abstract Objective To investigate the therapeutic effect of Gonadotropin-releasing Hormone Analogue (GnRHa)combined with Growth Hormone (rhGH) on children with idiopathic central precocious puberty (ICPP) and its influence on their height, estradiol (E2) and luteinizing hormone (LH). Methods A total of 68 cases of ICPP female children admitted to Maternal and Child Health Care Hospital of Dongguan City from January 2015 to June 2017 were selected and divided into the experimental group (35 cases) and the control group (33 cases) according to different medication conditions. The control group was treated with GnRHa, and the experimental group was treated with rhGH on the basis of the control group. The height, predicted adult height (PAH), standard difference of height (HtSDSBA), and the levels of LH, follicle stimulating hormone (FSH) and E2 before and after treatment of the two groups were compared. Results There were no significant differences in height, PAH and HtSDSBA between the two groups before treatment (P＞0.05).After treatment, the height, PAH and HtSDSBA of the two groups were higher than those before treatment, which in the experimental group were higher than those in the control group, and the differences were statistically significant (P＜0.05). There were no significant differences in the levels of LH, FSH after 60 minutes of GnRHa stimulation test and base E2 between the twol group before treatment (P＞0.05). After treatment, the levels of LH, FSH and base E2 in the two groups were higher than those before treatment, and which in the experimental group were higher than those in the control group, with statistically significant differences (P＜0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P＞0.05). Conclusion GnRHa combined with rhGH can significantly improve the predicted height of ICPP children, the levels of E2 and LH in vivo, and the drug is stable and safe. It can be put into use in children with unsatisfactory predicted adult height.
|
|
|
|
|
|
|
|
|
